Related Experiment Video
Updated: Nov 28, 2025
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for
Paul G Kluetz1, Patricia Keegan2, George D Demetri3,4
1Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland. paul.kluetz@fda.hhs.gov.
Abstract:
The FDA conducts independent reviews of scientific data obtained with investigational drug products to ensure that they are safe and effective. As a result of this process, FDA-approved product labeling is generated that is considered one of the most trusted sources of information for use of an approved drug. But FDA approval is only the beginning of the life cycle of a new drug; the first oncology drugs now have more than 7 decades of clinical experience in the postmarketing setting. Due, in part, to lack of incentives, some companies may not seek inclusion of new data, other than new safety information, in FDA-approved product labeling. Ensuring that product labeling provides adequate directions for use is important for all drugs, including older therapies that may form the backbone of many standard combination regimens for pediatric and adult cancers. Project Renewal is an FDA Oncology Center of Excellence pilot program that leverages expertise from the clinical and scientific oncology communities to review published literature and generate a drug-specific product report summarizing data that may support updates to FDA-approved product labeling. This article provides a broad overview of Project Renewal's collaborative pilot process for identifying and assessing literature supporting potential labeling updates, while engaging the oncology community to increase awareness of FDA's evidentiary standards and deliberative processes used when considering the addition of new indications and dosing regimens to product labeling.
Insights
Project Renewal enhances FDA drug labeling by reviewing postmarketing data with oncology experts. This pilot program ensures accurate cancer drug information for improved patient treatment and safety.
Area of Science:
- Oncology
- Drug Development
- Regulatory Science
Background:
- FDA-approved product labeling is a trusted source for drug information, but may not always reflect the latest postmarketing data.
- Lack of incentives can lead companies to omit new efficacy data from labeling, impacting treatment guidelines.
- Accurate labeling is crucial for both new and established therapies, especially in pediatric and adult cancer regimens.
Purpose of the Study:
- To introduce Project Renewal, a pilot program by the FDA Oncology Center of Excellence.
- To outline the collaborative process of reviewing scientific literature for potential updates to FDA-approved drug labeling.
- To enhance awareness of FDA's standards for adding new indications and dosing regimens.
Main Methods:
- Leveraging expertise from clinical and scientific oncology communities.
- Reviewing published literature to identify data supporting labeling updates.
- Generating drug-specific product reports for the FDA.
Main Results:
- Project Renewal facilitates a systematic review of postmarketing data.
- The program engages the oncology community in the labeling update process.
- It aims to ensure labeling reflects current scientific evidence and clinical experience.
Conclusions:
- Project Renewal is a vital initiative for updating oncology drug labeling.
- Collaboration with the oncology community strengthens the evidence base for labeling decisions.
- This process supports the safe and effective use of cancer therapies.